Flibanserin, the so-called “desire drug” that German pharma company Boehringer Ingelheim (BI) applied to the US FDA for approval, has received a resounding “no” vote by not only an FDA staff report but also by the FDA Advisory Panel charged with considering B-I’s application today. This comes via the live Twitter feed from the @NewViewCampaign.
UPDATE:
ABCnews.com reports on the unanimous “no” vote (11-0) by the FDA Advisory panel.
